BiotechTube

SHR7280 Tablets

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis, Uterine Fibroids, Assisted Reproduction

Trial Timeline

Apr 28, 2025 → Jun 5, 2025

NCT ID
NCT06949124

About SHR7280 Tablets

SHR7280 Tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06949124. Target conditions include Endometriosis, Uterine Fibroids, Assisted Reproduction.

What happened to similar drugs?

1 of 19 similar drugs in Endometriosis were approved

Approved (1) Terminated (3) Active (15)
✅Decapeptyl SR 11.25mgIpsenApproved
🔄40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
🔄Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
🔄Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
🔄ElagolixAbbViePhase 3
❌elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
🔄ElagolixAbbViePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06949124Phase 1Completed
NCT05082233Phase 2Completed

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
35
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
47
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
32
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
29
Placebo + ElagolixAbbViePhase 2
35
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
44
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
40
ElagolixAbbViePhase 3
40
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
32
Elagolix + placeboAbbViePhase 2
35
ElagolixAbbViePhase 3
40
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
35
elagolixAbbViePhase 3
40
ElagolixAbbViePhase 3
40
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
35
Gefapixant + Placebo + NaproxenMerckPhase 2
35
BGS649 + PlaceboNovartisPhase 2
27
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
35
LetrozoleNovartisPhase 2
35